Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.22B
EBITDA Margin
8.83%
TTM Avg
3.81%
3Y Avg
0.53%
5Y Avg
2.86%
Market Cap
$1.23B
EBITDA Margin
-2.25%
TTM Avg
-29.69%
3Y Avg
-65.15%
5Y Avg
-190.58%
Market Cap
$1.18B
EBITDA Margin
14.64%
TTM Avg
21.61%
3Y Avg
-2.02%
5Y Avg
-22.43%
Market Cap
$1.14B
EBITDA Margin
-234.91%
TTM Avg
-168.66%
3Y Avg
-182.22%
5Y Avg
-232.17%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | $1.21B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.21B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 8.83% | 3.81% | 0.53% | 2.86% |
| Cronos Group Inc. (CRON)vs › | $1.23B | -2.25% | -29.69% | -65.15% | -190.58% |
| MannKind Corporation (MNKD)vs › | $1.18B | 14.64% | 21.61% | -2.02% | -22.43% |
| Omada Health (OMDA)vs › | $1.23B | -2.49% | -12.68% | -37.94% | -37.94% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.14B | -234.91% | -168.66% | -182.22% | -232.17% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 28.28% | 32.08% | 32.10% | 26.80% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
